Suchen nach…

• TMEM16A inhibitors as a treatment option for cystic fibrosis

  B78025

  TMEM16A inhibitors as a treatment option for cystic fibrosis

  • TMEM16A inhibitors represent a causal treatment for cystic fibrosis
  • They reduce both excessive mucus formation and airway contraction
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs
• TMEM16A inhibitors as a treatment option for polycystic kidney disease (PKD)

  B79076

  TMEM16A inhibitors as a treatment option for polycystic kidney disease (PKD)

  • TMEM16A inhibitors represent a causative treatment for polycystic kidney disease
  • Significant suppression of renal cysts
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs
• Designed Chemokine-Selective Peptides in the Fight Against Atherosclerosis and Inflammation

  B80034

  Designed Chemokine-Selective Peptides in the Fight Against Atherosclerosis and Inflammation

  • Novel class of therapeutics for atherosclerotic plaques
  • Soluble peptide-based mimics of the CXCR4 receptor
  • High potency and target specificity
• When time is of the essence – Novel blood biomarker allows for a fast diagnosis of Type A aortic dissection

  X19012

  When time is of the essence – Novel blood biomarker allows for a fast diagnosis of Type A aortic dissection

  • Type A aortic dissection is a medical emergency
  • Novel protein biomarker for fast diagnosis
  • Easy blood-based testing
• Innovative 18F-labeled Norepinephrine analog PET tracers for broad diagnostic applications in neurology, cardiology and oncology

  B78129

  Innovative 18F-labeled Norepinephrine analog PET tracers for broad diagnostic applications in neurology, cardiology and oncology

  • Simple and low-cost synthesis and superior labeling efficiency
  • Extended tracer half-life and high PET signal strength
  • Widely applicable in neurology, oncology and cardiology

5 von 109 Tech Offers